Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alvotech
Alvotech underlined that it could “save US consumers and taxpayers billions annually,” after hitting a key landmark in its Phase III switching study for its high concentration 100mg/ml biosimilar Humira product.
In the latest twist in the tussle between Alvotech and AbbVie over Humira intellectual property, the originator has sued the Icelandic firm for a second time in a court in Illinois, in an attempt to enforce almost 60 patents that it says Alvotech has previously declined to litigate.
Alvotech has launched a US legal challenge over intellectual property around AbbVie’s Humira, claiming that the company enjoys a “wrongful monopoly” on the top-selling arthritis treatment for which the biosimilars company is developing a high-concentration adalimumab rival.
Alvotech has issued a robust rebuttal of accusations that it obtained AbbVie trade secrets relating to Humira for use in developing its biosimilar adalimumab rival.
- Generic Drugs
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Alvotech Iceland
- Alvotech Germany GmnH
- Alvotech Swiss AG